Literature DB >> 12761597

Rapid normalization of osseous FDG uptake following traumatic or surgical fractures.

Hongming Zhuang1, Joseph W Sam, Thomas K Chacko, Paulo S Duarte, Marc Hickeson, Qi Feng, Kozaim Z Nakhoda, Liang Guan, Phillip Reich, Shirley M Altimari, Abass Alavi.   

Abstract

It is known that following a traumatic fracture or surgical intervention, bone scintigraphy reveals positive results for an extended period of time, posing a challenge when evaluating patients for possible malignancy or superimposed osteomyelitis. Previous reports indicate that acute fractures can also result in increased fluorine-18 fluorodeoxyglucose (FDG) accumulation and therefore cause difficulties when patients are evaluated for other indications by FDG-PET. The purpose of this study was to assess the pattern and time course of abnormal FDG uptake following traumatic or surgical fracture. A total of 1,517 consecutive patients who underwent whole-body FDG-PET imaging were retrospectively studied. A history of fractures or orthopedic intervention was obtained from an interview prior to scanning. The FDG-PET results were compared with the results of other imaging studies, including bone scans, radiographs, CT, and MRI, as well as surgical pathology reports. Thirty-seven patients with a known date of traumatic or surgical fracture were identified. Among these, 14 had fractures or surgery within 3 months prior to FDG-PET, while 23 had fractures or surgical intervention greater than 3 months prior to FDG-PET. FDG-PET showed no abnormally increased uptake at the known fracture or surgical sites in 30 of these patients. Notably, in the 23 patients with fractures more than 3 months old, all but one showed no abnormally increased uptake. Furthermore, the positive FDG uptake in this exception was a result of complicating osteomyelitis. In the 14 patients with a history of fracture less than 3 months old, only six had abnormally increased FDG uptake. Following traumatic or surgical fractures, FDG uptake is expected to be normal within 3 months unless the process is complicated by infection or malignancy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761597     DOI: 10.1007/s00259-003-1198-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis.

Authors:  A Guhlmann; D Brecht-Krauss; G Suger; G Glatting; J Kotzerke; L Kinzl; S N Reske
Journal:  J Nucl Med       Date:  1998-12       Impact factor: 10.057

2.  Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases.

Authors:  T Kälicke; A Schmitz; J H Risse; S Arens; E Keller; M Hansis; O Schmitt; H J Biersack; F Grünwald
Journal:  Eur J Nucl Med       Date:  2000-05

3.  Increased F-18 FDG accumulation in an acute fracture.

Authors:  M Meyer; T Gast; S Raja; K Hubner
Journal:  Clin Nucl Med       Date:  1994-01       Impact factor: 7.794

4.  FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; H Ishijima; N Oya; N Sato; T Inoue; K Endo
Journal:  Radiology       Date:  2001-06       Impact factor: 11.105

5.  Fluorine-18 fluorodeoxyglucose-position emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections.

Authors:  F de Winter; C van de Wiele; D Vogelaers; K de Smet; R Verdonk; R A Dierckx
Journal:  J Bone Joint Surg Am       Date:  2001-05       Impact factor: 5.284

6.  FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy.

Authors:  C Franzius; J Sciuk; H E Daldrup-Link; H Jürgens; O Schober
Journal:  Eur J Nucl Med       Date:  2000-09

7.  [FDG-PET for diagnosis and follow-up of inflammatory processes: initial results from the orthopedic viewpoint].

Authors:  A Schmitz; H J Risse; T Kälicke; F Grünwald; O Schmitt
Journal:  Z Orthop Ihre Grenzgeb       Date:  2000 Sep-Oct

8.  Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging.

Authors:  H Zhuang; P S Duarte; M Pourdehand; D Shnier; A Alavi
Journal:  Clin Nucl Med       Date:  2000-04       Impact factor: 7.794

9.  Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.

Authors:  M Schulte; D Brecht-Krauss; B Heymer; A Guhlmann; E Hartwig; M R Sarkar; C G Diederichs; A Von Baer; J Kotzerke; S N Reske
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

10.  Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report.

Authors:  H C Wu; R F Yen; Y Y Shen; C H Kao; C C Lin; C C Lee
Journal:  J Cancer Res Clin Oncol       Date:  2002-08-13       Impact factor: 4.553

View more
  21 in total

1.  PET-positive fibrous dysplasia--a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery.

Authors:  Klaus Strobel; Beata Bode; Didier Lardinois; Ulrich Exner
Journal:  Skeletal Radiol       Date:  2006-05-20       Impact factor: 2.199

2.  The value of FDG-PET in patients with painful total knee arthroplasty.

Authors:  Katrin D M Stumpe; Jose Romero; Oliver Ziegler; Ehab M Kamel; Gustav K von Schulthess; Klaus Strobel; Juerg Hodler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-24       Impact factor: 9.236

3.  Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Authors:  Gang Cheng; Thomas C Kwee; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-22       Impact factor: 9.236

Review 4.  Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.

Authors:  Kathleen Carey; Babak Saboury; Sandip Basu; Alex Brothers; Alexis Ogdie; Tom Werner; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-14       Impact factor: 9.236

Review 5.  Radionuclide imaging of spinal infections.

Authors:  Filip Gemmel; Nicolas Dumarey; Christopher J Palestro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10       Impact factor: 9.236

6.  Spondylodiscitis: Diagnosis and Treatment Options.

Authors:  Christian Herren; Norma Jung; Miguel Pishnamaz; Marianne Breuninger; Jan Siewe; Rolf Sobottke
Journal:  Dtsch Arztebl Int       Date:  2017-12-25       Impact factor: 5.594

Review 7.  Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging.

Authors:  Ali Gholamrezanezhad; Kyle Basques; Ali Batouli; George Matcuk; Abass Alavi; Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2018-06       Impact factor: 3.959

Review 8.  Current molecular imaging of spinal tumors in clinical practice.

Authors:  Nora Sandu; Gabriele Pöpperl; Marie-Elisabeth Toubert; Toma Spiriev; Belachew Arasho; Mikael Orabi; Bernhard Schaller
Journal:  Mol Med       Date:  2011-01-03       Impact factor: 6.354

9.  Diagnostic value of 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis.

Authors:  Anna Hartmann; Karim Eid; Claudio Dora; Otmar Trentz; Gustav K von Schulthess; Katrin D M Stumpe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-29       Impact factor: 9.236

Review 10.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.